摘要
理想的生物标志物是实现阿尔茨海默病(AD)早期精确诊断和预测疾病发展的重要前提。新版AD诊断标准从临床无症状期到痴呆阶段的区分也有赖于生物标志物的应用。介绍目前临床应用的AD生物标志物及其在药物研发中的应用,重点对AD血液生物标志物研究的现状和瓶颈进行综述。
Ideal biomarkers are critical to precise diagnosis of Alzheimer＇s disease （AD） at early stage and prediction of disease progression. Newly issued diagnostic guidelines for AD also depends on biomarkers to identify different stages of AD from asymptomatic stage to dementia. In this paper, AD biomarkers used in current clinical practice were reviewed with emphasis on recent advances and bottlenecks in the research of blood-based AD biomarkers.
出处
《药学进展》
CAS
2016年第8期564-570,共7页
Progress in Pharmaceutical Sciences
基金
国家"重大新药创制"科技重大专项(No.2009ZX09103-077
No.2012ZX09303-003)
国家自然科学基金(No.81671375
No.81373351)
